Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 21   

Articles published

KYTH 37.61 +0.76 (2.06%)
price chart
Commit To Purchase Kythera Biopharmaceuticals At $30, Earn 12.1 ...
Investors considering a purchase of Kythera Biopharmaceuticals, Inc. (Symbol: KYTH) shares, but cautious about paying the going market price of $37.18/share, might benefit from considering selling puts among the alternative strategies at their disposal.
KYTHERA Biopharmaceuticals Submits New Drug Submission to Health ...
WESTLAKE VILLAGE, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational drug, ...
Related articles »  
Stock Highlights: Kythera Biopharmaceuticals (NASDAQ:KYTH), FireEye ...
On 11 AUG Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational drug, ATX-101 (deoxycholic acid), as an injectable treatment for the ...
Insider Selling: KYTHERA Biopharmaceuticals CEO Unloads 1828 Shares of ...
KYTHERA Biopharmaceuticals logo KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith R. Leonard unloaded 1,828 shares of KYTHERA Biopharmaceuticals stock on the open market in a transaction that occurred on Monday, August 4th. The shares ...
Hot Stocks: Mediabistro Inc. (NASDAQ:MBIS), NCR Corp. (NYSE:NCR), Kythera ...
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) on 7 August announced GAAP Net loss was $19.5 million for the second quarter of 2014, compared to $12.3 million for the second quarter of 2013.
Insider Selling: KYTHERA Biopharmaceuticals Director Sells 1505 Shares of ...
The company reported ($3.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.67) by $2.51. Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year.
KYTHERA Biopharmaceuticals CEO Unloads $119917 in Stock (KYTH)  WKRB News
Related articles »  
KYTHERA Biopharmaceuticals CEO Sells $64163 in Stock (KYTH)
Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
KYTHERA Biopharmaceuticals CEO Keith R. Leonard Sells 1828 Shares (KYTH)  Ticker Report
Related articles »  
Morning Buzz: GW Pharmaceuticals (NASDAQ:GWPH), Kythera ...
On 7 AUG Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) reported financial results for its second quarter 2014 and provided an update on recent accomplishments.
Hot Stock List : Infoblox Inc. (NYSE:BLOX), Google (NASDAQ:GOOG), Sapient ...  WallStreet Scope
Related articles »  
Investors Are Watching : Verizon Communications (NYSE:VZ), Ultra Clean ...
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its second quarter 2014 and provided an update on recent accomplishments.
KYTHERA Biopharmaceuticals Releases Second Quarter 2014 Operating Results
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Related articles »